Literature DB >> 34183369

Novel Role for Macrophage Galactose-Type Lectin-1 to Regulate Innate Immunity against Mycobacterium tuberculosis.

Kubra F Naqvi1, Matthew B Huante1, Tais B Saito2, Mark A Endsley1, Benjamin B Gelman2, Janice J Endsley3.   

Abstract

Tuberculosis (TB) caused by infection with Mycobacterium tuberculosis is characterized by inflammatory pathology and poorly understood mechanisms of innate immunity. Pattern recognition receptors, expressed on the surface of macrophages, determine the balance of inflammatory and antimicrobial functions that influence disease outcome. Carbohydrate moieties displayed by mycobacteria can serve as pattern recognition receptor ligands for some members of the C-type lectin receptor (CLR) family, interactions that mediate a variety of incompletely understood immune outcomes. This work identifies a novel role for the CLR macrophage galactose-type lectin (MGL)-1 in a mouse model (C57BL/6 and MGL-1-/-) of experimental TB. Murine macrophages upregulated MGL-1 following in vitro exposure to M. tuberculosis, whereas MGL+ cells accumulated at sites of mycobacteria-driven inflammation in the lung. Pulmonary macrophages from MGL-1-deficient mice displayed increased production of proinflammatory cytokines (IL-1β, IL-6, and IFN-γ) that were associated with greater lipid accumulation, following M. tuberculosis infection. Surprisingly, for a CLR, we also observed MGL-1-dependent antimycobacterial activity as evidenced by greater M. tuberculosis proliferation in bone marrow-derived macrophages, and the lung, of MGL-1-deficient mice. Differential transcriptome analysis further revealed that loss of MGL-1 perturbs the activation of various genes involved in the regulation of inflammation and lipid metabolism in the setting of M. tuberculosis infection. These results identify MGL-1 signaling as an important mechanism that regulates innate immunity against M. tuberculosis and indicates the potential for the MGL pathway as a novel therapeutic target for anti-TB immunity.
Copyright © 2021 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34183369      PMCID: PMC8702441          DOI: 10.4049/jimmunol.2001276

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  68 in total

1.  PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties.

Authors:  M Amine Bouhlel; Bruno Derudas; Elena Rigamonti; Rébecca Dièvart; John Brozek; Stéphan Haulon; Christophe Zawadzki; Brigitte Jude; Gérard Torpier; Nikolaus Marx; Bart Staels; Giulia Chinetti-Gbaguidi
Journal:  Cell Metab       Date:  2007-08       Impact factor: 27.287

2.  C-type lectins in immune defense against pathogens: the murine DC-SIGN homologue SIGNR3 confers early protection against Mycobacterium tuberculosis infection.

Authors:  Antoine Tanne; Olivier Neyrolles
Journal:  Virulence       Date:  2010 Jul-Aug       Impact factor: 5.882

3.  Human Macrophage Galactose-Type Lectin (MGL) Recognizes the Outer Core of Escherichia coli Lipooligosaccharide.

Authors:  Meriem Maalej; Rosa Ester Forgione; Roberta Marchetti; François Bulteau; Michel Thépaut; Rosa Lanzetta; Cedric Laguri; Jean-Pierre Simorre; Franck Fieschi; Antonio Molinaro; Alba Silipo
Journal:  Chembiochem       Date:  2019-06-24       Impact factor: 3.164

Review 4.  Innate immune recognition of Mycobacterium tuberculosis.

Authors:  Johanneke Kleinnijenhuis; Marije Oosting; Leo A B Joosten; Mihai G Netea; Reinout Van Crevel
Journal:  Clin Dev Immunol       Date:  2011-04-07

5.  The C-type lectin receptor CLECSF8/CLEC4D is a key component of anti-mycobacterial immunity.

Authors:  Gillian J Wilson; Mohlopheni J Marakalala; Jennifer C Hoving; Arjan van Laarhoven; Rebecca A Drummond; Bernhard Kerscher; Roanne Keeton; Esther van de Vosse; Tom H M Ottenhoff; Theo S Plantinga; Bachti Alisjahbana; Dhirendra Govender; Gurdyal S Besra; Mihai G Netea; Delyth M Reid; Janet A Willment; Muazzam Jacobs; Sho Yamasaki; Reinout van Crevel; Gordon D Brown
Journal:  Cell Host Microbe       Date:  2015-02-11       Impact factor: 21.023

6.  An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides.

Authors:  Laura L Eggink; Katherine F Roby; Robert Cote; J Kenneth Hoober
Journal:  J Immunother Cancer       Date:  2018-04-17       Impact factor: 13.751

Review 7.  Mycobacterium tuberculosis Infection-Driven Foamy Macrophages and Their Implications in Tuberculosis Control as Targets for Host-Directed Therapy.

Authors:  Dahee Shim; Hagyu Kim; Sung Jae Shin
Journal:  Front Immunol       Date:  2020-05-12       Impact factor: 7.561

8.  The C-Type Lectin Receptor DC-SIGN Has an Anti-Inflammatory Role in Human M(IL-4) Macrophages in Response to Mycobacterium tuberculosis.

Authors:  Geanncarlo Lugo-Villarino; Anthony Troegeler; Luciana Balboa; Claire Lastrucci; Carine Duval; Ingrid Mercier; Alan Bénard; Florence Capilla; Talal Al Saati; Renaud Poincloux; Ivanela Kondova; Frank A W Verreck; Céline Cougoule; Isabelle Maridonneau-Parini; Maria Del Carmen Sasiain; Olivier Neyrolles
Journal:  Front Immunol       Date:  2018-06-12       Impact factor: 7.561

9.  A murine DC-SIGN homologue contributes to early host defense against Mycobacterium tuberculosis.

Authors:  Antoine Tanne; Bo Ma; Frédéric Boudou; Ludovic Tailleux; Hélène Botella; Edgar Badell; Florence Levillain; Maureen E Taylor; Kurt Drickamer; Jérome Nigou; Karen M Dobos; Germain Puzo; Dietmar Vestweber; Martin K Wild; Marie Marcinko; Peter Sobieszczuk; Lauren Stewart; Daniel Lebus; Brigitte Gicquel; Olivier Neyrolles
Journal:  J Exp Med       Date:  2009-09-21       Impact factor: 14.307

Review 10.  Signalling through C-type lectin receptors: shaping immune responses.

Authors:  Teunis B H Geijtenbeek; Sonja I Gringhuis
Journal:  Nat Rev Immunol       Date:  2009-07       Impact factor: 53.106

View more
  1 in total

Review 1.  Seminal Plasma Glycoproteins as Potential Ligands of Lectins Engaged in Immunity Regulation.

Authors:  Beata Olejnik; Mirosława Ferens-Sieczkowska
Journal:  Int J Environ Res Public Health       Date:  2022-08-23       Impact factor: 4.614

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.